GE gets clearance for NT workstations

Article

GE Medical Systems has received Food and Drug Administration 510(k) clearance for its Platinum line of Windows NT-based diagnostic and clinical review workstations. The workstations, which will also employ Java technology, are scheduled for a

GE Medical Systems has received Food and Drug Administration 510(k) clearance for its Platinum line of Windows NT-based diagnostic and clinical review workstations. The workstations, which will also employ Java technology, are scheduled for a fourth-quarter commercial release, according to the Milwaukee company.

The regulatory approval marks an important milestone for GE in its quest for PACS market dominance. With customer interest centering on systems based on the Microsoft platform, many market watchers consider a lack of an NT-based offering a liability. GE's PACS is currently based on the Macintosh platform.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.